Fortun Holdings posts record Q3 funding volume of $4.18 million, up 41% year over year
Bitget2026/10/06 13:01Fortun Holdings funded about $4.18 million in Q3 2026, up 40.7% from $2.97 million a year earlier. Funding rose 23.5% from $3.39 million in Q2; internal funding was $3.92 million, up 39.9% year over year. Internally funded volume represented about 94% of Q3 funding, versus about 89% in the prior quarter. Total transactions reached 696, up 50.3% sequentially; internally funded transactions rose to 677, up 54.9%. Cash collections were about $3.87 million, up 24.6% year over year; fees collected excluding NSF-related fees were $1.05 million, up 32.6%. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fortun Holdings Corp. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202610060900ACCESSWRNAPR_____1233460) on October 06, 2026, and is solely responsible for the information contained therein.
- Fortun Holdings funded about $4.18 million in Q3 2026, up 40.7% from $2.97 million a year earlier.
- Funding rose 23.5% from $3.39 million in Q2; internal funding was $3.92 million, up 39.9% year over year.
- Internally funded volume represented about 94% of Q3 funding, versus about 89% in the prior quarter.
- Total transactions reached 696, up 50.3% sequentially; internally funded transactions rose to 677, up 54.9%.
- Cash collections were about $3.87 million, up 24.6% year over year; fees collected excluding NSF-related fees were $1.05 million, up 32.6%.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Former BioNTech executive leads Bambusa Therapeutics (BBTX.US) in sprint to Nasdaq, "boosting" eczema drug trials
Bambusa Therapeutics Inc. has filed for an initial public offering, planning to raise funds for clinical trials of treatments for eczema and other inflammatory diseases.
JPMorgan raises AbbVie target price to $300